Compare Stocks: MNKD, TLX, RLAY, and CELC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$79.64 +0.2%	$88.50	$44.42 ▼ $151.02	$3.89B	0.19	844,550 shs	559,820 shs
MNKD MannKind	$3.35 +0.3%	$3.88	$2.23 ▼ $6.51	$1.07B	1.1	4.07 million shs	2.08 million shs
RLAY Relay Therapeutics	$17.69 +1.3%	$19.15	$5.01 ▼ $21.27	$3.83B	1.69	3.45 million shs	1.84 million shs
TLX Telix Pharmaceuticals	$11.62 +1.5%	$11.37	$6.28 ▼ $13.11	$3.89B	-0.17	430,157 shs	850,090 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	0.00%	-1.35%	-10.09%	-22.43%	+57.15%
MNKD MannKind	0.00%	-5.65%	-15.44%	-21.23%	-39.60%
RLAY Relay Therapeutics	0.00%	-7.27%	-6.93%	-11.50%	+237.91%
TLX Telix Pharmaceuticals	0.00%	-9.05%	+1.42%	+1.33%	+14.73%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$79.64 +0.2%	$88.50	$44.42 ▼ $151.02	$3.89B	0.19	844,550 shs	559,820 shs
MNKD MannKind	$3.35 +0.3%	$3.88	$2.23 ▼ $6.51	$1.07B	1.1	4.07 million shs	2.08 million shs
RLAY Relay Therapeutics	$17.69 +1.3%	$19.15	$5.01 ▼ $21.27	$3.83B	1.69	3.45 million shs	1.84 million shs
TLX Telix Pharmaceuticals	$11.62 +1.5%	$11.37	$6.28 ▼ $13.11	$3.89B	-0.17	430,157 shs	850,090 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	0.00%	-1.35%	-10.09%	-22.43%	+57.15%
MNKD MannKind	0.00%	-5.65%	-15.44%	-21.23%	-39.60%
RLAY Relay Therapeutics	0.00%	-7.27%	-6.93%	-11.50%	+237.91%
TLX Telix Pharmaceuticals	0.00%	-9.05%	+1.42%	+1.33%	+14.73%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELC Celcuity	2.83	Moderate Buy	$154.75	94.31% Upside
MNKD MannKind	2.50	Moderate Buy	$8.34	149.07% Upside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	46.50% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$20.50	76.42% Upside

Current Analyst Ratings Breakdown

Latest MNKD, TLX, RLAY, and CELC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/23/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
9/21/2026	TLX Telix Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy
9/17/2026	CELC Celcuity	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$157.00
9/15/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/14/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
9/11/2026	MNKD MannKind	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
9/3/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/2/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/1/2026	CELC Celcuity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	TLX Telix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELC Celcuity	N/A	N/A	N/A	N/A	$2.17 per share	N/A
MNKD MannKind	$348.97M	3.09	$0.06 per share	53.98	($0.17) per share	-19.71
RLAY Relay Therapeutics	$15.35M	252.55	N/A	N/A	$3.27 per share	5.41
TLX Telix Pharmaceuticals	$803.79M	4.91	$0.04 per share	271.56	$1.23 per share	9.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELC Celcuity	-$177.04M	-$4.30	N/A	N/A	N/A	N/A	-350.78%	-41.54%	11/11/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.13	N/A	N/A	N/A	-11.08%	-11.21%	-6.31%	11/4/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	43.04	N/A	N/A	N/A	N/A	N/A

Latest MNKD, TLX, RLAY, and CELC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	-$1.44	-$0.28	-$1.44	$4.42 million	N/A
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
8/5/2026	Q2 2026	MNKD MannKind	-$0.0075	-$0.01	-$0.0025	-$0.06	$108.08 million	$109.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELC Celcuity	6.04	8.93	8.93
MNKD MannKind	N/A	1.72	1.41
RLAY Relay Therapeutics	N/A	18.27	18.27
TLX Telix Pharmaceuticals	1.16	2.01	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELC Celcuity	63.33%
MNKD MannKind	49.55%
RLAY Relay Therapeutics	96.98%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CELC Celcuity	13.33%
MNKD MannKind	2.60%
RLAY Relay Therapeutics	5.04%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELC Celcuity	155	48.93 million	42.41 million	Optionable
MNKD MannKind	592	321.54 million	313.18 million	Optionable
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.89 million	N/A	N/A

MNKD, TLX, RLAY, and CELC Headlines

Recent News About These Companies

Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - Here's Why

September 28 at 2:24 PM | marketbeat.com

Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Has Average Price Target of $20.50 According to Brokerages

September 28 at 2:46 AM | americanbankingnews.com

Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Now Rated "Buy" by Wall Street Brokerages

September 28 at 2:13 AM | marketbeat.com

Analysts Offer Insights on NA Companies: Ford Motor (F) and Telix Pharmaceuticals Limited Unsponsored ADR (TLX)

September 26 at 6:38 PM | theglobeandmail.com

Telix Pharmaceuticals (NASDAQ:TLX) Stock Rating Reaffirmed as Buy by HC Wainwright

September 25 at 10:41 AM | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Should You Sell?

September 25 at 5:21 AM | americanbankingnews.com

Wedbush Reaffirms "Outperform" Rating for Telix Pharmaceuticals (NASDAQ:TLX)

September 25 at 1:54 AM | americanbankingnews.com

Telix Pharmaceuticals Issues New Shares Under Employee Stock Plan

September 25 at 1:30 AM | tipranks.com

Bell Potter Securities upgrades Telix Pharmaceuticals to buy from hold

September 24, 2026 | msn.com

Telix Pharmaceuticals (ASX:TLX): ITM Deal Shifts Valuation

September 24, 2026 | kalkinemedia.comK

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up on Analyst Upgrade

September 24, 2026 | americanbankingnews.com

Telix Pharmaceuticals (ASX:TLX) ITM Deal Puts Valuation Back In Focus

September 23, 2026 | finance.yahoo.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's Why

September 23, 2026 | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from Wedbush

September 23, 2026 | marketbeat.com

What could Telix Pharmaceuticals (ASX:TLX) mean for Healthcare Stocks?

September 23, 2026 | kalkinemedia.comK

Telix Pharmaceuticals (ASX:TLX) Lands $2.35 Billion Deal To Reshape Radiopharmaceutical Reach

September 23, 2026 | finance.yahoo.com

Telix (TLX) to Buy Germany’s ITM for up to $2.35 Billion to Lock in its Cancer Isotope Supply

September 22, 2026 | insidermonkey.com

Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript

September 22, 2026 | seekingalpha.com

Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day - Slideshow

September 22, 2026 | seekingalpha.com

Herbert Smith Freehills Kramer advises Telix Pharmaceuticals Limited on its transformational merger with ITM Isotope Technologies Munich SE

September 22, 2026 | legaldesire.comL

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up After Analyst Upgrade

September 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD, TLX, RLAY, and CELC Company Descriptions

Celcuity NASDAQ:CELC

$79.64 +0.12 (+0.15%)

Closing price 04:00 PM Eastern

Extended Trading

$79.62 -0.02 (-0.02%)

As of 07:43 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

MannKind NASDAQ:MNKD

$3.35 +0.01 (+0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$3.36 +0.01 (+0.39%)

As of 07:56 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Relay Therapeutics NASDAQ:RLAY

$17.69 +0.22 (+1.26%)

Closing price 04:00 PM Eastern

Extended Trading

$17.48 -0.21 (-1.16%)

As of 07:43 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$11.62 +0.17 (+1.48%)

Closing price 04:00 PM Eastern

Extended Trading

$11.75 +0.13 (+1.11%)

As of 07:49 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNKD, TLX, RLAY, and CELC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNKD, TLX, RLAY, and CELC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNKD, TLX, RLAY, and CELC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD, TLX, RLAY, and CELC Company Descriptions

Celcuity NASDAQ:CELC

MannKind NASDAQ:MNKD

Relay Therapeutics NASDAQ:RLAY

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNKD, TLX, RLAY, and CELC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNKD, TLX, RLAY, and CELC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNKD, TLX, RLAY, and CELC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD, TLX, RLAY, and CELC Company Descriptions

Celcuity NASDAQ:CELC

MannKind NASDAQ:MNKD

Relay Therapeutics NASDAQ:RLAY

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools